Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-predictable routine of meetings, deadlines, and the like has, of course returned. To cope, yes, we are firing up the coffee kettle and brewing a few needed cups of stimulation. We are starting today with chocolate cherry decadence. Feel free to join us, or if you prefer, grab a bottle of water. Meanwhile, here are a few items of interest to get you going. Hope all goes well today and you conquer the world …

GlaxoSmithKline (GSK) agreed to buy Tesaro (TSRO) for $5.1 billion, gaining a class of cancer drugs called PARP inhibitors that work by blocking an enzyme that cancer cells use to repair damage in their DNA, STAT writes. PARP inhibitors are believed to be active in ovarian and prostate cancers, and are being studied in combination with immunotherapy drugs. The deal is expected to allow the big drug maker to “develop wholly owned combination therapies in multiple tumor types,” Glaxo chief executive Emma Walmsley says.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy